Orforglipron hype on TikTok: what the trials actually show

What did @myrajoinmochi actually say?

The creator walked through Eli Lilly's orforglipron trial results, saying the oral GLP-1 pill hit "14.7% was the max weight loss over just 36 weeks" in the highest dose group, with "87 to 90% of patients" losing at least 5% of body weight. They also flagged a significant side effect burden, noting nausea rates of roughly 41-50% and overall adverse event rates of 86-97% depending on dose. Their bottom line: promising for people who hate needles, but side effect rates are a "big number" worth watching.

This is a competent, broadly accurate summary of a real dataset. The creator didn't overclaim a cure, didn't push a specific dose, and explicitly said they want more trial data before getting fully excited. That kind of restraint is rarer than it should be on TikTok.

Does the science back this up?

Yes, with some important nuances. The 14.7% figure comes from Eli Lilly's Phase 2 orforglipron trial published in 2023 in the New England Journal of Medicine (Wharton et al., 2023, NEJM). That trial enrolled 272 adults with obesity or overweight plus at least one weight-related condition and ran across multiple dose cohorts over 36 weeks.

The 14.7% body weight reduction was observed in the highest dose arm, and the placebo-corrected loss was closer to 12%. That distinction matters. The creator cited the raw number, not the placebo-adjusted figure, which is the more scientifically meaningful one. The 87-90% achieving 5% weight loss is also supported by the trial data. The nausea figures, roughly 41-48% in higher dose groups, align with what was reported, though the framing of "86-97% had side effects" reflects the broadest adverse event category, not just gastrointestinal issues.

• Wharton S, et al. (2023). Orforglipron for adults with obesity. New England Journal of Medicine, 389(10), 877-888.
• Drucker DJ (2022). GLP-1 physiology informs the pharmacotherapy of obesity. Nature Reviews Endocrinology, 18(7), 408-423.

What did they get wrong (or right)?

Mostly right, but there's a meaningful omission. The creator reported the 14.7% weight loss as if it stands cleanly on its own. It doesn't. Placebo-adjusted weight loss is the number that tells you what the drug actually did versus what diet, monitoring, and the trial environment did. That adjusted figure was roughly 12.4% in the top dose group, still impressive, but not 14.7%.

The comparison to tirzepatide and semaglutide on side effects is fair directionally. Injectable GLP-1 agonists do tend to show lower GI adverse event rates in their pivotal trials, likely because subcutaneous delivery bypasses the gut-level concentration spike that oral GLP-1 formulations produce. The creator correctly identifies this as "the big holdup with the oral form." That is accurate pharmacology.

They also correctly named orforglipron as a non-peptide GLP-1 receptor agonist, which matters, since its small-molecule structure means it doesn't require the fatty acid coating that oral semaglutide (Rybelsus) needs for absorption. That's a real and relevant distinction they implied without spelling out.

One thing missing from the video: this was Phase 2 data. Phase 3 trials are ongoing. Applying Phase 2 effect sizes to clinical expectations is a habit that frequently comes back to bite people.

What should you actually know?

Orforglipron is genuinely interesting, but it is not approved, not available, and the Phase 2 sample size was small. 272 people across multiple arms is not a lot of signal to bet on. Phase 3 data, which Lilly is running now, will tell us whether these numbers hold at scale and across more diverse populations.

The side effect comparison to injectables deserves more scrutiny than the video gave it. Nausea rates of 41-48% are high. In the SURMOUNT-1 tirzepatide trial (Jastreboff et al., 2022, NEJM), nausea occurred in about 28-33% of patients. That's a meaningful gap. For someone who is injection-averse, trading a needle for a 50% chance of significant nausea is not obviously a better deal.

Finally, "pill form GLP-1" is an appealing category but oral semaglutide already exists as Rybelsus. The conversation about oral GLP-1s isn't brand new, and orforglipron's actual differentiation will depend on how its absorption profile, dosing flexibility, and long-term tolerability compare head-to-head, data that does not yet exist.